Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress
22 Maggio 2023 - 2:05PM
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the
“Company”), a clinical-stage pharmaceutical company now focused on
developing the next generation of chemotherapeutic drugs to improve
the efficacy and safety for patients suffering from cancer, today
announces CEO David Young, Pharm.D., Ph.D. will participate in a
panel at the World Orphan Drug Congress to be held at the Gaylord
National Resort & Convention Center in Washington, D.C. May
23-25, 2023. Dr. Young will also be providing a corporate overview
of Processa Pharmaceuticals, as well as be available for meetings
with potential pharmaceutical and biotech partners during the
conference.
The panel, titled “Clinical Development &
Regulatory Panel Session: Patient focused drug development - best
practices on patient group and drug developer interaction with FDA”
will be held on May 24, 2023 at 4:20 PM ET. His presentation will
be a Pitch and Partner presentation titled, “Applying FDA’s Project
Optimus to the Next Generation of Chemotherapy Drugs Treating Rare
Cancers.” This presentation will be held on May 24 at 1:00 PM ET in
Theater 6.
For those with interest in meeting with the
Company, please inquire via dyoung@processapharma.com. The Company
will be available for partnering discussions throughout the
conference.
About Processa Pharmaceuticals,
Inc.
Processa is a clinical stage pharmaceutical
company focused on developing the Next Generation Chemotherapy
(NGC) drugs to improve the safety and efficacy of cancer treatment.
By combining Processa’s novel oncology pipeline with proven
cancer-killing active molecules and the Processa Regulatory Science
Approach as well as experience in defining Optimal Dosage Regimens
for FDA approvals, Processa not only will be providing better
therapy options to cancer patients but also increase the
probability of FDA approval for its Next Generation Chemotherapy
(NGC) drugs following an efficient path to approval. Processa’s NGC
drugs are modifications of existing FDA-approved oncology drugs
resulting in an alteration of the metabolism and/or distribution of
these FDA-approved drugs while maintaining the existing mechanisms
of killing the cancer cells. The company’s approach to drug
development is based on more than 30 years of drug development
expertise to efficiently design and conduct clinical trials that
demonstrate a positive benefit/risk relationship. The Processa team
has a track record of obtaining over 30 approvals for indications
across almost every division of FDA. Using its proven Regulatory
Science Approach, the Processa Team has experience defining the
Optimal Dosage Regimen using the principles of the FDA’s Project
Optimus Oncology initiative. The advantages of Processa’s NGCs are
expected to include fewer patients experiencing side effects that
lead to dose discontinuation, more significant cancer response and
a greater number of patients -- in excess of 200,000 for each NGC
drug -- who will benefit from each NGC drug. Currently under
development are three next generation chemotherapy oncology
treatments: Next Generation Capecitabine (PCS6422 and capecitabine
to treat metastatic colorectal, gastrointestinal, breast,
pancreatic, and other cancers), Next Generation Gemcitabine
(PCS3117 to treat pancreatic, lung, ovarian, breast, and other
cancers), and Next Generation Irinotecan (PCS11T to treat lung,
colorectal, gastrointestinal, pancreatic, and other cancers).
For more information, visit our website at
www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking
statements. The statements in this press release that are not
purely historical are forward-looking statements which involve
risks and uncertainties. Actual future performance outcomes and
results may differ materially from those expressed in
forward-looking statements. Please refer to the documents filed by
Processa Pharmaceuticals with the SEC, specifically the most recent
reports on Forms 10-K and 10-Q, which identify important risk
factors which could cause actual results to differ from those
contained in the forward-looking statements.
For More
Information:Investors:Bret ShapiroCORE
IRir@processapharma.com
Company Contact:Patrick Lin(925)
683-3218plin@processapharma.com
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Lug 2023 a Lug 2024